FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

And the plot thick­ens. No­var­tis $NVS of­fi­cials are re­port­ed­ly now scram­bling to ex­plain to the FDA why it took them two months to open an in­ter­nal in­ves­ti­ga­tion in­to da­ta dis­crep­an­cies for their $2.1 mil­lion gene-ther­a­py for spinal mus­cu­lar dy­s­tro­phy — the world’s most ex­pen­sive drug.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN